ClinicalTrials.gg
Not yet recruitingNCT07464977EMGRTSAUpdated May 7, 2026

EMG and Delta Function in Standard RTSA vs Lateralization

An interventional study of Lateralization of glenoid component and Standard implantation technique in Cuff Tear Arthropathy, Omarthrosis and Rotator Cuff Tear Arthropathy, sponsored by Vienna Hospital Association. Not yet recruiting at 1 site in Austria. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Vienna Hospital Association · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
60 Years to 85 Years
Sex
All
01

Study summary

Reverse total shoulder arthroplasty (RTSA) is a well-established method to treat patients with irreparable rotator cuff tears and glenohumeral osteoarthritis. The biomechanical principle implies a medialization and distalization of the center of rotation (COR). Deficiencies in internal and external rotation constitute frequently encountered functional problems. Some studies showed reduced activation of the posterior deltoid in EMG measurements, which may explain the inability to compensate these movements. Lateralized prosthetic designs demonstrated increased external rotation through an alteration of the deltoid's lever arm.

The aim of the study is to investigate the impact of lateralization on functional outcome and deltoid EMG activity in comparison to a standard implantation technique.

Read the detailed description

Introduction Reverse total shoulder arthroplasty (RTSA) is a well-established method to treat patients with irreparable rotator cuff tears and glenohumeral osteoarthritis. The biomechanical principle is a medialization and distalization of the center of rotation (COR) to provide a compensatory role for the insufficient rotator cuff. Deficiencies in internal and external shoulder rotation constitute frequently seen functional problems. Some studies showed reduced activation of the posterior deltoid in EMG measurements, which may explain the inability to compensate these movements. Lateralized prosthetic designs implants demonstrated increased external rotation force through an alteration of the deltoid's lever arm.

Material and Methods This study will be conducted as a monocentric randomized, prospective trial. Approximately 130 patients, scheduled for reversed total shoulder arthroplasty (RSA), will be enrolled. The patients will be divided into two groups depending on receiving RSA or a lateralized implant via randomization. Preoperatively and at 4 follow-up visits, a surface EMG (sEMG) of the deltoid muscle will be conducted and clinical scores (Constant-Murley Score and Quick DASH questionnaire) will be assessed. As patient related outcome measures, p-ASES-S and SVV will be evaluated. Pre- and postoperative x-rays and CT scans will be conducted for preoperative planning and measurement of achieved lateralization. Clinical and radiological complications will be routinely documented. Group comparisons and correlations will be performed to compare both groups pre- and postoperatively. The study's duration is scheduled for 2 years.

Aim of the Study The aim of the study is to evaluate a possible difference in function and EMG activity between the two patient groups. Especially a different increase in external rotation range of motion and strength shall be investigated. Furthermore a possible connection between preoperative deltoid muscle activity and postoperative outcome shall be pointed out. Lastly, the impact of lateralization on functional outcome, shall be evaluated compared to the standard implantation technique.

02

Conditions studied

  • Cuff Tear Arthropathy
  • Omarthrosis
  • Rotator Cuff Tear Arthropathy

Keywords

  • reverse total shoulder arthroplasty
  • cuff tear arthropathy
  • lateralization
  • deltoid function
  • EMG
03

In context

Rotator Cuff Tear Arthropathy

57 studies on the registry are indexed under Rotator Cuff Tear Arthropathy; 15 are open to participants now.

This study's planned enrollment of 130 is above the median of 90 across 33 interventional studies indexed under Rotator Cuff Tear Arthropathy.

Browse Rotator Cuff Tear Arthropathy studies →

Lead sponsor

Vienna Hospital Association is the lead sponsor of 11 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male/female, 60-85y
  • diagnosis of Cuff tear arthropathy (CTA)
  • irreparable rotator cuff tear
  • severe osteoarthritis (OA)
  • primary RSA
  • verified rotator cuff tear in preoperative MRI
  • absence of severe cognitive impairment

Exclusion criteria

Exclusion Criteria:

  • previous muscle transfer
  • revision surgery
  • highly dysplastic glenoid
  • axillary nerve palsy
  • upper limb radiculopathy
  • cervical myelopathy
  • degenerative muscular disease,
  • previous proximal humeral fracture
  • revision arthroplasty
  • rheumatoid arthritis
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
130 participants (estimated)

Study arms

  • Active comparator
    Standard Implantation Group

    Subjects treated with a standard glenoid component of the used reverse total shoulder prosthesis

    Device: Standard implantation technique

  • Active comparator
    Lateralized Implantation Group

    Subjects treated with a lateralized glenoid component of the used reverse total shoulder prosthesis

    Device: Lateralization of glenoid component

Interventions

  • DeviceLateralization of glenoid component

    Lateralization of glenoid component in reverse total shoulder arthroplasty via metal augment on the glenoid side with a thickness of at least 4mm

  • DeviceStandard implantation technique

    Implantation of a standard glenoid component without any lateralization via metal back on the glenoid site

06

What researchers measure

Primary outcomes

  1. Delta Muscle activity (especially posterior Delta part)

    The ratio between peak torque and EMG root mean square is measured

    Time frame: preoperative

  2. Delta Muscle activity (especially posterior Delta part)

    The ratio between peak torque and EMG root mean square is measured

    Time frame: 6 weeks postoperative

  3. Delta Muscle activity (especially posterior Delta part)

    The ratio between peak torque and EMG root mean square is measured

    Time frame: 3 months postoperative

  4. Delta Muscle activity (especially posterior Delta part)

    The ratio between peak torque and EMG root mean square is measured

    Time frame: 6 months postoperative

  5. Delta Muscle activity (especially posterior Delta part)

    The ratio between peak torque and EMG root mean square is measured

    Time frame: 1 year postoperative

Secondary outcomes

  1. Range of movement (forward flexion, abduction, external rotation, extension)

    ROM (range of movement) measured with a goniometer according to neutral zero method

    Time frame: preoperative

  2. Range of movement (forward flexion, abduction, external rotation, extension)

    ROM (range of movement) measured with a goniometer according to neutral zero method

    Time frame: 6 weeks postoperative

  3. Range of movement (forward flexion, abduction, external rotation, extension)

    ROM (range of movement) measured with a goniometer according to neutral zero method

    Time frame: 3 months postoperative

  4. Range of movement (forward flexion, abduction, external rotation, extension)

    ROM (range of movement) measured with a goniometer according to neutral zero method

    Time frame: 6 months postoperative

  5. Range of movement (forward flexion, abduction, external rotation, extension)

    ROM (range of movement) measured with a goniometer according to neutral zero method

    Time frame: 1 year postoperative

  6. Objective and subjective outcome scores / Quality of life scores

    Constant score (0-100) (higher = better)

    Time frame: preoperative, 6 weeks postoperative, 3 months postoperative, 6 months postoperative, 12 months postoperative

  7. Objective and subjective outcome scores / Quality of life scores

    SVV (subjective shoulder value) (0-100%) (higher = better)

    Time frame: preoperative, 6 weeks postoperative, 3 months postoperative, 6 months postoperative, 12 months postoperative

  8. Objective and subjective outcome scores / Quality of life scores

    p-ASES (patient-reported American Shoulder and Elbow Surgeons Score) (0-100) (higher = better)

    Time frame: preoperative, 6 weeks postoperative, 3 months postoperative, 6 months postoperative, 12 months postoperative

  9. Objective and subjective outcome scores / Quality of life scores

    Quick-DASH (Quick-Disability of Arm, Shoulder and Hand) (0-100) (higher = better)

    Time frame: preoperative, 6 weeks postoperative, 3 months postoperative, 6 months postoperative, 12 months postoperative

  10. Difference in lateralization between preoperative 3D CT-based planning and postoperative CT-based implant position

    Lateralization will be quantitatively assessed by comparing preoperative and postoperative computed tomography (CT) scans. The preoperative CT scan will be used for 3D planning and virtual implantation. The postoperative CT scan will be used to determine the actually achieved implant position. The original preoperative joint line will serve as the reference value. Medialization or lateralization will be measured as the linear distance (in millimeters) between the preoperative joint line and the postoperative implant position. The achieved lateralization will be calculated based on this difference. Additionally, the planned lateralization from the preoperative 3D virtual implantation will be compared with the actually achieved lateralization measured on the postoperative CT scan. The primary metric will be the absolute and mean deviation (in millimeters) between planned and achieved lateralization, allowing assessment of the accuracy of the preoperative 3D planning.

    Time frame: Preoperative and 1 year postoperative

  11. Humeral Length (Millimeters) Measured on Standardized Radiographs

    Humeral length will be measured in millimeters on standardized anteroposterior radiographs of the entire humerus obtained according to the Lädermann protocol. Measurements will be performed by comparing preoperative and postoperative radiographs. The primary metric will be the absolute difference in humeral length between preoperative and postoperative images. Measurements will be performed using calibrated digital imaging software by blinded reviewers.

    Time frame: preoperative, 6 weeks postoperative, 3 months postoperative, 6 months postoperative, 12 months postoperative

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Aug 2027, 14 months later.

Of 20 interventional studies with no phase under Rotator Cuff Tear Arthropathy, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 72. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2024
First posted
Mar 11, 2026
StartEst.
Jun 2026
Primary completionEst.
Aug 2027
CompletionEst.
Dec 2027
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07464977
Lead sponsor
Vienna Hospital Association
Responsible party
Sponsor
First posted
Mar 11, 2026
Start date
Jun 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
May 7, 2026

Study contacts

Robert Breuer, MD
Contact
robert.breuer@meduniwien.ac.at
00430128802 ext. 743429
Valentin Pichler, MD
Contact
valentin.pichler@gesundheitsverbund.at
00430128802 ext. 743400
Robert Breuer, MD
principal investigator · Vienna HA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion